ClinicalTrials.gg
RecruitingNCT06784193Updated Oct 5, 2026

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of OP-3136 and Fulvestrant in Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), sponsored by Olema Pharmaceuticals, Inc.. Recruiting at 25 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Olema Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Oct 5, 2026First sites in 4 new countriesSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
674th of 2,995
180 · median 56
Started
2024
with 157 others
Phase 1
927 of 3,368
134 open now
Primary completion
2027-05
later than 378 of 892 live
Registered
3,133rd of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 674th largest by planned enrollment of the 2,995 interventional ones that give a count, is one of 158 that started in 2024, is one of 927 in phase 1, reaches primary completion later than 378 of the 892 other live ones, and was the 3,133rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, as monotherapy and in combination with other anticancer agents in participants with advanced solid tumors.

This study consists of 2 parts: a dose escalation part (Part 1) and dose expansion part (Part 2).

Read the detailed description

Part 1A (Dose Escalation for OP-3136 Monotherapy): This part of the study will evaluate the safety, tolerability, and PK in a range of doses of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, administered orally once daily to participants with ER+ HER2- advanced or metastatic breast cancer (mBC), advanced or metastatic castration resistant prostate cancer (mCRPC), or advanced or metastatic non-small cell lung cancer (mNSCLC), and determine the maximum tolerated dose (MTD) and the recommended dose/regimen for expansion (RDE).

Part 1B (Dose Escalation for OP-3136 in Combination with Fulvestrant): This part of the study will evaluate the safety and PK of OP-3136 administered in combination with fulvestrant in participants with ER+ HER2- mBC, and determine MTD and RDE for this combination.

Part 1C (Dose Escalation for OP-3136 in Combination with Palazestrant): This part of the study will evaluate the safety and PK of OP-3136 administered in combination with palazestrant in participants with ER+ HER2- mBC, and determine MTD and RDE for this combination.

Part 2A (Dose Expansion for OP-3136 Monotherapy): This part will evaluate two expansion cohorts at the monotherapy RDE from part 1 in participants with ER+ HER2- mBC and participants with mCRPC.

Part 2B (Dose Expansion for OP-3136 in Combination with Fulvestrant OR Palazestrant): This part will evaluate the RDEs for OP-3136 in combination with fulvestrant from Part 1B OR the RDEs of OP-3136 in combination with palazestrant in an expansion cohort in participants with ER+ HER2- mBC.

03

Conditions studied

  • Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)
  • Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  • Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Metastatic Breast Cancer
  • Fulvestrant
  • Palazestrant

Keywords

  • KAT6 Inhibitor
  • Histone Acetyltransferase (HAT) Inhibitor
  • Epigenetic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants with advanced or ER+- breast cancer, mCRPC, or NSCLC (Part 1) or advanced or metastatic ER+HER2- BC or mCRPC (Part 2).
  • Part 1A (Dose escalation for OP-3136 monotherapy): Participants must have a tumor that is unresectable or metastatic and for which life prolonging measures do not exist or available therapies are intolerable or no longer effective.
  • Part 1B (Dose escalation for OP-3136 in combination with fulvestrant): Participants with advanced or metastatic ER+ HER2- breast cancer that have progressed on or after at least 1 that included endocrine therapy and CDK 4/6 inhibitor in advanced or metastatic setting and must have received no more than 2 prior lines of endocrine therapy (one of which must be in combination with CDK4/6 inhibitor) and no more than 1 prior line of chemotherapy or an antibody-drug conjugate in the advanced or metastatic setting.
  • Part 1C (Dose escalation for OP-3136 in combination with palazestrant): Participants with advanced or metastatic ER+ HER2- breast cancer that have progressed on or after at least 1 prior line of treatment that included endocrine therapy and CDK 4/6 inhibitor in advanced or metastatic setting and must have received no more than 2 prior lines of endocrine therapy (one of which must be in combination with CDK4/6 inhibitor) and no more than 1 prior line of chemotherapy or an antibody-drug conjugate in the advanced or metastatic setting.
  • Part 2A (Dose Expansion in ER+ HER2- mBC for OP-3136 monotherapy): Participants must have received up to 3 prior lines of endocrine therapy (one of which must be in combination with CDK4/6 inhibitor) and up to 1 prior line of chemotherapy or an antibody-drug conjugate.
  • Part 2A (Dose Expansion in mCRPC for OP-3136 monotherapy): Participants must have received up to 4 lines of prior systemic therapy for prostate cancer. Prior therapy must include treatment with an androgen receptor pathway inhibitor(s).
  • Part 2B (Dose Expansion in ER+ HER2- mBC for OP-3136 in combination with fulvestrant OR Dose Expansion in ER+ HER2- mBC for OP-3136 in combination with palazestrant): Participants must have progressed on or after at least 1 prior line of treatment that included endocrine therapy and CDK 4/6 inhibitor in advanced or metastatic setting. Participants must have received no more than 2 prior lines of endocrine therapy in the advanced or metastatic setting and no more than 1 prior line of chemotherapy or an antibody-drug conjugate in the advanced or metastatic setting.

Key Exclusion Criteria:

  • Prior therapy with KAT6A/B inhibitor in any treatment setting.
  • Participants with advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term.
  • Known active or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, , or a spinal cord compression that require CNS-specific treatment, or participants who did not demonstrate clinical and radiologic stability during the last 2 months prior to the first dose of study treatment or require or are currently on therapy for .
  • History of cerebral vascular disease, including , within 6 months prior to the first dose of study treatment.
  • History of or ongoing impaired cardiac function or cardiac disease within 6 months prior to the first dose of study treatment.

Note: Additional inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Part 1A Dose Escalation monotherapy

    Drug: OP-3136

  • Experimental
    Part 1B Dose Escalation in combination with fulvestrant

    Drug: OP-3136 · Drug: Fulvestrant

  • Experimental
    Part 1C Dose Escalation in combination with palazestrant

    Drug: OP-3136 · Drug: Palazestrant

  • Experimental
    Part 2A Dose Expansion monotherapy - mBC

    Drug: OP-3136

  • Experimental
    Part 2A Dose Expansion monotherapy - mCRPC

    Drug: OP-3136

  • Experimental
    Part 2B Dose Expansion in combination with fulvestrant OR palazestrant-mBC @ RDE 1

    Drug: OP-3136 · Drug: Fulvestrant · Drug: Palazestrant

  • Experimental
    Part 2B Dose Expansion in combination with fulvestrant OR palazestrant-mBC @ RDE 2

    Drug: OP-3136 · Drug: Fulvestrant · Drug: Palazestrant

Interventions

  • DrugOP-3136

    Selective inhibitor of HAT enzymes KAT6A and KAT6B

  • Selective estrogen receptor degrader (SERD)

  • Complete estrogen receptor antagonist (CERAN)

06

What researchers measure

Primary outcomes

  1. Number of participants with dose-limiting toxicities in the Dose Escalation Arms

    Time frame: Up to 28 days

  2. Incidence of adverse events and laboratory abnormalities

    Time frame: Up to 26 months

Secondary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: Up to 26 months

  2. Time to maximum concentration (Tmax)

    Time frame: Up to 26 months

  3. Area under the curve from time zero to 24 hours (AUC0-24)

    Time frame: Up to 26 months

  4. Overall Response Rate (ORR)

    Time frame: Up to 26 months

  5. Duration of Response (DOR)

    Time frame: Up to 26 months

  6. Clinical Benefit Rate (CBR)

    Time frame: Up to 26 months

07

Study locations

24 of 25 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for May 2027, 29 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 29 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2025
First posted
Jan 20, 2025
StartActual
Dec 16, 2024
Primary completionEst.
May 30, 2027
CompletionEst.
Aug 30, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
17 sites added — first sites in France, Hong Kong, Ireland and Spain. University Medical Center - New Orleans is now Terminated
Show 17 added (6 United States, 3 Australia, 3 France, 3 Spain, 1 Hong Kong, 1 Ireland)
  • Banner MD Anderson Cancer Center · Gilbert, United States
  • University of Colorado · Aurora, United States
  • Massachusetts General Hospital · Boston, United States
  • Memorial Sloan Kettering Cancer Center · New York, United States
  • The Ohio State University · Columbus, United States
  • Tennessee Oncology · Nashville, United States
  • The Kinghorn Cancer Centre · Darlinghurst, Australia
  • Liverpool Hospital · Liverpool, Australia
  • Macquarie University Clinical Trials Unit · Macquarie, Australia
  • Institut De Cancerologie De L'ouest · Saint-Herblain, France
  • Hôpital Paris Saint-Joseph · Paris, France
  • Institut Gustave Roussy · Villejuif, France
  • Queen Mary Hospital · Hong Kong, Hong Kong
  • START Dublin · Dublin, Ireland
  • START - Barcelona · Barcelona, Spain
  • Start - Fjd · Madrid, Spain
  • START Madrid - CIOCC · Madrid, Spain
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    17 sites added — first sites in France, Hong Kong, Ireland and Spain. University Medical Center - New Orleans is now Terminated
    Show 17 added (6 United States, 3 Australia, 3 France, 3 Spain, 1 Hong Kong, 1 Ireland)
    • Banner MD Anderson Cancer Center · Gilbert, United States
    • University of Colorado · Aurora, United States
    • Massachusetts General Hospital · Boston, United States
    • Memorial Sloan Kettering Cancer Center · New York, United States
    • The Ohio State University · Columbus, United States
    • Tennessee Oncology · Nashville, United States
    • The Kinghorn Cancer Centre · Darlinghurst, Australia
    • Liverpool Hospital · Liverpool, Australia
    • Macquarie University Clinical Trials Unit · Macquarie, Australia
    • Institut De Cancerologie De L'ouest · Saint-Herblain, France
    • Hôpital Paris Saint-Joseph · Paris, France
    • Institut Gustave Roussy · Villejuif, France
    • Queen Mary Hospital · Hong Kong, Hong Kong
    • START Dublin · Dublin, Ireland
    • START - Barcelona · Barcelona, Spain
    • Start - Fjd · Madrid, Spain
    • START Madrid - CIOCC · Madrid, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06784193
Lead sponsor
Olema Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jan 20, 2025
Start date
Dec 16, 2024
Primary completion
May 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

There may be multiple sites in this clinical trial Olema Clinical Trial Lead
Contact
clinical@olema.com
415-651-7206
Olema Medical Study Director
Contact

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion